> top > projects > ASCO_abstracts > docs
ASCO_abstracts  

Documents (3,155) JSON TSV

source DB source ID text size updated at # proj. # Ann. updated_at
asco@alo33 162201 Background: Combination D+T improves the overall survival OS of patients pts ith V600 BRAF-mutation positive advanced melanoma. D+T is currently being explored in an adjuvant study of pts ith re 2.41 KB 2023-01-16 1 2023-01-16
asco@alo33 162203 Background: Collection efficiency CE of an apharesis machine refers to the proportion of cells passing through it that is harvested. A higher collection efficiency reduces the need for repeated ap 2.25 KB 2023-01-16 1 2023-01-16
asco@alo33 162217 Background: LPS is one of the most common subtypes of soft tissue sarcoma STS . In this retrospective analysis, e describe the outcome and prognostic factors of advanced LPS in a tertiary referral 2.21 KB 2023-01-16 1 2023-01-16
asco@alo33 162226 Background: Colorectal cancer CRC is a highly curable and preventable carcinoma if detected early, and the to most idely-accepted CRC screening tests are the fecal occult blood test FOBT and col 2.28 KB 2023-01-16 1 2023-01-16
asco@alo33 162230 Background: Female survivors of childhood cancers are at increased risk for NSPM, cessation of menses prior to age 40 not secondary to resection of reproductive organs. Our aims ere to assess preval 2.31 KB 2023-01-16 1 2023-01-16
asco@alo33 162234 Background: PD-1 inhibitor-related pneumonitis is an uncommon but serious immune-related adverse event irAE . Details of radiographic patterns of this entity remain to be investigated. Methods: Pat 2.32 KB 2023-01-16 1 2023-01-16
asco@alo33 162238 Background: PD-1 inhibitors are promising anti-cancer agents and are associated ith unique immune-related response patterns. We characterized patterns of tumor response dynamics on CT scans during P 2.35 KB 2023-01-16 1 2023-01-16
asco@alo33 162239 Background: Sip-T is an FDA-approved immunotherapy for patients pts ith asymptomatic or minimally symptomatic metastatic CRPC. Sip-T is manufactured from autologous peripheral blood mononuclear ce 2.28 KB 2023-01-16 1 2023-01-16
asco@alo33 162242 Background: Side effects are associated ith discontinuation of and non-adherence to aromatase inhibitor AI treatment among breast cancer patients. Musculoskeletal pain is a ell-documented side eff 2.29 KB 2023-01-16 1 2023-01-16
asco@alo33 162299 Background: Mutational status in colorectal cancer CRC impacts response to EGFR inhibition, prognosis, and may affect response to chemoradiation. It is unclear if obesity or other clinical charact 2.31 KB 2023-01-16 1 2023-01-16